FrankG.HaluskaMD

Oncology • Boston, MA

Physician

Join to view full profile

Are you Dr. Haluska?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
750 Washington St
Nemc Box #836
Boston, MA 02111
Phone+1 617-636-5000

Summary

Dr. Frank Haluska, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1995
Massachusetts General HospitalResidency, Internal Medicine, 1989 - 1991
Perelman School of Medicine at the University of PennsylvaniaClass of 1989

Certifications & Licensure

MA State Medical License 1991 - 2025

Clinical Trials

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Start of enrollment: 2000 Aug 01
Completed
Phase 3
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) Start of enrollment: 2003 May 01
Completed
Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) Start of enrollment: 2004 Jun 01
Completed
Phase 2
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) Start of enrollment: 2005 May 01
Completed
Phase 2
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) Start of enrollment: 2005 May 01
Completed
Phase 1
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) Start of enrollment: 2005 Aug 01
Completed
Phase 2
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) Start of enrollment: 2008 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
Suzanne George, Margaret von Mehren, Jonathan A Fletcher, Jichao Sun, Sen Zhang
Clinical Cancer Research. 2022-04-01
364 citations
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette
Blood. 2018-07-26
407 citations
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong Wan Kim, Marcello Tiseo, Myung-Ju Ahn, Karen L. Reckamp, Karin Holmskov Hansen
Journal of Clinical Oncology. 2017-05-05

Press Mentions

Anchiano Appoints Steve DiPalma as Chief Financial OfficerMay 5th, 2020
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare ConferenceSeptember 20th, 2019
Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment ConferenceSeptember 3rd, 2019
Join now to see all

Grant Support

Genetics Of RAS, PTEN, BRAF And CDKN2A In MelanomaNational Cancer Institute2006
Genetics Of RAS, PTEN, BRAF And CDKN2A In MelanomaNational Cancer Institute2005
Peptide-Pulsed Dendritic Cell Therapy For MelanomaNational Cancer Institute1999–2000